General healthcare issues related to generic and biosimilar industries.
2025 · 1st Quarter (Jan 1 - Mar 31)
FRESENIUS KABI USA LLC
Filed by FEROX STRATEGIES.
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 17, 2025
- Income
- $50,000.00
- Expenses
- Not reported
- Registrant
- FEROX STRATEGIES
- Client
- FRESENIUS KABI USA LLC
- Filing UUID
- 5640a8ab-ff6e-4ab6-9b04-3bcd34d6eeff
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
General patent issues related to generic and biosimilar industries.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.